Trevi completes enrollment in Phase 2b/3 PRISM trial for Haduvio in prurigo nodularis; top-line data expected Q2 2022

Trevi Therapeutics, Inc.

PRISM trial enrolled ~360 subjects with severe pruritus and prurigo nodularis.
Trial evaluates Haduvio (nalbuphine ER) 162 mg versus placebo twice daily.
Primary endpoint: ≥4-point improvement in weekly mean WI-NRS at Week 14 vs baseline.
FDA previously granted Fast Track designation for nalbuphine ER in PN pruritus.
Top-line data expected in Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.